Learn More
Key Words: Ca 2ϩ /calmodulin-dependent protein kinase II Ⅲ sarcoplasmic reticulum Ca 2ϩ leak Ⅲ atrial fibrillation Ⅲ Ca 2ϩ sparks Ⅲ ryanodine receptor A trial fibrillation (AF) is the most frequent sustained arrhythmia in clinical practice. 1 In AF, both structural and electrophysiological remodeling of the atrial myocardium occurs, leading to increased(More)
Rationale: Heart failure (HF) is known to be associated with increased Ca 2؉ /calmodulin-dependent protein kinase (CaMK)II expression and activity. There is still controversial discussion about the functional role of CaMKII in HF. Moreover, CaMKII inhibition has never been investigated in human myocardium. Objective: We sought to investigate detailed(More)
BACKGROUND Transgenic (TG) Ca/calmodulin-dependent protein kinase II (CaMKII)delta(C) mice have heart failure and isoproterenol (ISO)-inducible arrhythmias. We hypothesized that CaMKII contributes to arrhythmias and underlying cellular events and that inhibition of CaMKII reduces cardiac arrhythmogenesis in vitro and in vivo. METHODS AND RESULTS Under(More)
A trial fibrillation (AF) is the most common sustained arrhythmia. AF produces lifestyle-limiting symptoms and increases the risk of stroke and death, 1 but current therapies have limited efficacy. The renin-angiotensin system is upreg-ulated in cardiovascular disease, and elevated angiotensin II (Ang II) favors AF. Ang II activates NADPH oxidase, leading(More)
RATIONALE Telethonin (also known as titin-cap or t-cap) is a 19-kDa Z-disk protein with a unique β-sheet structure, hypothesized to assemble in a palindromic way with the N-terminal portion of titin and to constitute a signalosome participating in the process of cardiomechanosensing. In addition, a variety of telethonin mutations are associated with the(More)
  • 1